. Tuesday Bristol-Myers Squibb announced on, 7 September, 2010 its intent to acquire ZymoGenetics. Upon the successful closing of the tender offer, shareholders of ZymoGenetics will receive $9.75 in cash for each share of ZymoGenetics common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following a purchase of shares in the tender offer, ZymoGenetics shall become a subsidiary of Bristol-Myers Squibb. Bristol-Myers Squibb will document today with the U.S. Securities and Exchange Commission a tender offer statement on Plan TO which provides the conditions of the tender present.Related StoriesAustralian researchers find a way to boost cross-protective capabilities of influenza A vaccineEnsemble models provide accurate real-time estimates of current and impending flu activityNew national report on use of antiviral drugs to treat, prevent influenzaScientists today believe the H5N1 virus is becoming more resilient and in a position to stay alive longer in higher temperature ranges and in moist conditions, which could mean the it poses a risk all year round instead of on a seasonal basis.